Biogen just delivered a solid Q2 beat, smashing revenue and earnings forecasts with $2.48 billion in sales—up slightly from last year. But the outlook dims for the next quarter, with analysts expecting an 8% revenue drop. Despite that, investor sentiment remains steady, as Biogen’s history of surprises keeps analysts confident. As the first major biotech firm to report a drop this season, Biogen’s performance is setting the tone for the entire sector—while its stock has dipped recently, biotech overall is holding steady.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
